NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
Sellas Life Sciences Group
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
Fred Hutchinson Cancer Center